@article{7b6215cfb5c14fb5bf351b5a5e440a26,
title = "Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment",
abstract = "Elevated hippocampal activation is observed in conditions that confer risk for Alzheimer's disease, including amnestic mild cognitive impairment (aMCI). Studies in relevant animal models have indicated that overactivity in selective hippocampal circuits contributes to cognitive impairment. Here, we tested the effect of reducing hippocampal activation in aMCI. Under placebo treatment, hippocampal activation in the dentate gyrus/CA3 was elevated in aMCI patients compared to a healthy control group. By using a low dose of the antiepileptic levetiracetam hippocampal activation in aMCI was reduced to a level that did not differ from the control group. Compared to aMCI memory performance under placebo, performance in the scanning task was significantly improved under drug treatment. Contrary to the view that greater hippocampal activation might serve a beneficial function, these results support the view that increased hippocampal activation in aMCI is a dysfunctional condition and that targeting excess hippocampal activity has therapeutic potential.",
author = "Arnold Bakker and Krauss, {Gregory L.} and Albert, {Marilyn S.} and Speck, {Caroline L.} and Jones, {Lauren R.} and Stark, {Craig E.} and Yassa, {Michael A.} and Bassett, {Susan S.} and Shelton, {Amy L.} and Michela Gallagher",
note = "Funding Information: We would like to thank Dr. Jason Brandt, Dr. Paul Dash, Dr. Argye Hillis-Trupe, Dr. Majid Fotuhi, and Dr. Peter Rabins for help with participant recruitment and the staff of the F.M. Kirby Center for Functional Brain Imaging and Alica Diehl, Benjamin Drapcho, and Christina Li for their assistance with data collection. This work was supported by NIH grant RC2AG036419 to M.G. M.G. is the founder of AgeneBio. She is an inventor on Johns Hopkins University intellectual property with patents pending and licensed to AgeneBio, and she consults for the company and owns company stock, which is subject to certain restrictions under University policy. M.G.'s role in the current study was in compliance with the conflict of interest policies of the Johns Hopkins School of Medicine. G.L.K. is an investigator and received research support from UCB Pharma. ",
year = "2012",
month = may,
day = "10",
doi = "10.1016/j.neuron.2012.03.023",
language = "English (US)",
volume = "74",
pages = "467--474",
journal = "Neuron",
issn = "0896-6273",
publisher = "Cell Press",
number = "3",
}